Reactive oxygen species-dependent destruction of MEK and Akt in Manumycin stimulated death of lymphoid tumor and myeloma cell lines

International Journal of Cancer

Volumn 122, Issue 7, 2008, Pages 1496-1505

  Sears, Khandra T ^a   Daino, Hanako ^a   Carey, Gregory B ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

Akt; Caspase; Cleavage; Farnesyltransferase inhibitor; Manumycin; MEK; Ras; Reactive oxygen species

Indexed keywords

CASPASE 9; CATALASE; COMPLEMENTARY DNA; MANUMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; SUPEROXIDE DISMUTASE; THIOREDOXIN REDUCTASE; AMIDE; CASPASE; ENZYME INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; POLYENE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; CELL MATURATION; CELL SURVIVAL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LYMPHATIC SYSTEM TUMOR; MYELOMA CELL; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN TRANSPORT; SIGNAL PROCESSING; TUMOR CELL; TUMOR GROWTH; DRUG EFFECT; LYMPHOMA; METABOLISM; MULTIPLE MYELOMA; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; LYMPHOMA; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MULTIPLE MYELOMA; PHOSPHORYLATION; POLYENES; POLYUNSATURATED ALKAMIDES; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; SUPEROXIDES;

EID: 39649107753     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23207     Document Type: Article

References (56)

1. Shaw RJ, Cantley LC. Ras, Pl(3)K and mTOR signalling controls tumour cell growth. Nature 2006;441:424-30.
2. Murphy LO, Blenis J. MAPK signal specificity: the right place at the right time. Trends Biochem Sci 2006;31:268-75.
3. Sebti SM, Adjei AA. Farnesyltransferase inhibitors. Semin Oncol 2004;31:28-39.
4. De Vita G, Bauer L, da Costa VM, De Felice M, Baratta MG, De Menna M, Di Lauro R. Dose-dependent inhibition of thyroid differentiation by RAS oncogenes. Mol Endocrinol 2005;19:76-89.
5. Morioka CY, Saito S, Machado MC, Ohzawa K, Kubrusly MS, Cunha JE, Watanabe A. Antisense therapy specific to mutated K-ras gene in hamster pancreatic cancer model. Can it inhibit the growth of 5-FU and MMC-resistant metastatic and remetastatic cell lines? In Vivo 2004;18:113-17.
6. Adjei AA, Davis JN, Erlichman C, Svingen PA, Kaufmann SH. Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res 2000;6:2318-25.
7. Farh L, Mitchell DA, Deschenes RJ. Farnesylation and proteolysis are sequential, but distinct steps in the CaaX box modification pathway. Arch Biochem Biophys 1995;318:113-21.
8. Winter-Vann AM, Casey PJ. Post-prenylation-processing enzymes as new targets in oncogenesis. Nat Rev Cancer 2005;5:405-12.
9. Shapiro P. Ras-MAP kinase signaling pathways and control of cell proliferation: relevance to cancer therapy. Crit Rev Clin Lab Sci 2002;39:285-330.
10. Hara M, Akasaka K, Akinaga S, Okabe M, Nakano H, Gomez R, Wood D, Uh M, Tamanoi F. Identification of Ras farnesyltransferase inhibitors by microbial screening. Proc Natl Acad Sci USA 1993;90:2281-5.
11. Mazzocca A, Giusti S, Hamilton AD, Sebti SM, Pantaleo P, Carloni V. Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines. Mol Pharmacol 2003;63:159-66.
12. Zhou JM, Zhu XF, Pan QC, Liao DF, Li ZM, Liu ZC. Manumycin induces apoptosis in human hepatocellular carcinoma HepG2 cells. Int J Mol Med 2003;12:955-9.
13. Pan J, Yeung SC. Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors. Cancer Res 2005;65:9109-12.
14. Kainuma O, Asano T, Hasegawa M, Kenmochi T, Nakagohri T, Tokoro Y, Isono K. Inhibition of growth and invasive activity of human pancreatic cancer cells by a farnesyltransferase inhibitor, manumycin. Pancreas 1997;15:379-83.
15. Frassanito MA, Cusmai A, Piccoli C, Dammacco F. Manumycin inhibits farnesyltransferase and induces apoptosis of drug-resistant interleukin 6-producing myeloma cells. Br J Haematol 2002;118:157-65.
16. Pan J, She M, Xu ZX, Sun L, Yeung SC. Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells. Cancer Res 2005;65:3671-81.
17. Devadas S, Hinshaw JA, Zaritskaya L, Williams MS. Fas-stimulated generation of reactive oxygen species or exogenous oxidative stress sensitize cells to Fas-mediated apoptosis. Free Radic Biol Med 2003;35:648-61.
18. Heo J, Campbell SL. Superoxide anion radical modulates the activity of Ras and Ras-related GTPases by a radical-based mechanism similar to that of nitric oxide. J Biol Chem 2005;280:12438-45.
19. Kwon J, Qu CK, Maeng JS, Falahati R, Lee C, Williams MS. Receptor-stimulated oxidation of SHP-2 promotes T-cell adhesion through SLP-76-ADAP. EMBO J 2005;24:2331-41.
20. Chandra J, Samali A, Orrenius S. Triggering and modulation of apoptosis by oxidative stress. Free Radic Biol Med 2000;29:323-33.
21. Hampton MB, Orrenius S. Dual regulation of caspase activity by hydrogen peroxide: implications for apoptosis. FEBS Lett 1997;414:552-6.
22. Mueller CM, Scott DW. Distinct molecular mechanisms of Fas resistance in murine B lymphoma cells. J Immunol 2000;165:1854-62.
23. Oi VT, Morrison SL, Herzenberg LA, Berg P. Immunoglobulin gene expression in transformed lymphoid cells. Proc Natl Acad Sci USA 1983;80:825-9.
24. Gururajan M, Chui R, Karuppannan AK, Ke J, Jennings CD, Bondada S. c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells. Blood 2005;106:1382-91.
25. Carey GB, Scott DW. Role of phosphatidylinositol 3-kinase in anti-IgM- and anti-IgD-induced apoptosis in B cell lymphomas. J Immunol 2001;166:1618-26.
26. Fang W, Rivard JJ, Ganser JA, LeBien TW, Nath KA, Mueller DL, Behrens TW. Bcl-xL rescues WEHI 231 B lymphocytes from oxidant-mediated death following diverse apoptotic stimuli. J Immunol 1995;155:66-75.
27. Huynh CK, Brodie AM, Njar VC. Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice. Br J Cancer 2006;94:513-23.
28. Chatfield K, Eastman A. Inhibitors of protein phosphatases 1 and 2A differentially prevent intrinsic and extrinsic apoptosis pathways. Biochem Biophys Res Commun 2004;323:1313-20.
29. Scaduto RC Jr, Grotyohann LW. Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives. Biophys J 1999;76:469-77.
30. Rottenberg H, Wu S. Quantitative assay by flow cytometry of the mitochondrial membrane potential in intact cells. Biochim Biophys Acta 1998;1404:393-404.
31. Castedo M, Hirsch T, Susin SA, Zamzami N, Marchetti P, Macho A, Kroemer G. Sequential acquisition of mitochondrial and plasma membrane alterations during early lymphocyte apoptosis. J Immunol 1996;157:512-21.
32. Hinshaw JA, Mueller CM, Scott DW, Williams MS. B cell receptor signaling mediates immediate protection from Fas-induced apoptosis upstream of caspase activation through an atypical protein kinase C isozyme and de novo protein synthesis. Eur J Immunol 2003;33:2490-500.
33. Liochev SI, Fridovich I. Carbon dioxide mediates Mn(II)-catalyzed decomposition of hydrogen peroxide and peroxidation reactions. Proc Natl Acad Sci USA 2004;101:12485-90.
34. Becker CF, Hunter CL, Seidel R, Kent SB, Goody RS, Engelhard M. Total chemical synthesis of a functional interacting protein pair: the protooncogene H-Ras and the Ras-binding domain of its effector c-Raf1. Proc Natl Acad Sci USA 2003;100:5075-80.
35. Drake J, Kanski J, Varadarajan S, Tsoras M, Butterfield DA. Elevation of brain glutathione by γ-glutamylcysteine ethyl ester protects against peroxynitrite-induced oxidative stress. J Neurosci Res 2002;68:776-84.
36. Pan J, Yeung SC. Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors. Cancer Res 2005;65:9109-12.
37. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998;391:43-50.
38. Schlaeger EJ, Schumpp B. Propagation of a mouse myeloma cell line J558L producing human CD4 immunoglobulin G1. J Immunol Methods 1992;146:111-20.
39. Bras A, Ruiz-Vela A, Gonzalez de Buitrago G, Martinez AC. Caspase activation by BCR cross-linking in immature B cells: differential effects on growth arrest and apoptosis. FASEB J 1999;13:931-44.
40. Heck DE, Kagan VE, Shvedova AA, Laskin JD. An epigrammatic (abridged) recounting of the myriad tales of astonishing deeds and dire consequences pertaining to nitric oxide and reactive oxygen species in mitochondria with an ancillary missive concerning the origins of apoptosis. Toxicology 2005;208:259-71.
41. Egger L, Schneider J, Rheme C, Tapernoux M, Hacki J, Borner C. Serine proteases mediate apoptosis-like cell death and phagocytosis under caspase-inhibiting conditions. Cell Death Differ 2003;10:1188-203.
42. Vera Y, Rodriguez S, Castanares M, Lue Y, Atienza V, Wang C, Swerdloff RS, Sinha Hikim AP. Functional role of caspases in heat-induced testicular germ cell apoptosis. Biol Reprod 2005;72:516-22.
43. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK/STAT. Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004;18:189-218.
44. Johnson DE. Noncaspase proteases in apoptosis. Leukemia 2000;14:1695-703.
45. Gentil B, Grimot F, Riva C. Commitment to apoptosis by ceramides depends on mitochondrial respiratory function, cytochrome c release and caspase-3 activation in Hep-G2 cells. Mol Cell Biochem 2003;254:203-10.
46. Zhang Q, Tsukahara F, Maru Y. N-acetyl-cysteine enhances growth in BCR-ABL-transformed cells. Cancer Sci 2005;96:240-4.
47. Ritsick DR, Edens WA, McCoy JW, Lambeth JD. The use of model systems to study biological functions of Nox/Duox enzymes. Biochem Soc Symp 2004;71:85-96.
48. Seno T, Inoue N, Gao D, Okuda M, Sumi Y, Matsui K, Yamada S, Hirata KI, Kawashima S, Tawa R, Imajoh-Ohmi S, Sakurai H, et al. Involvement of NADH/NADPH oxidase in human platelet ROS production. Thromb Res 2001;103:399-409.
49. Jackson SH, Devadas S, Kwon J, Pinto LA, Williams MS. T cells express a phagocyte-type NADPH oxidase that is activated after T cell receptor stimulation. Nat Immunol 2004;5:818-27.
50. Schumann MA, Leung CC, Raffin TA. Activation of NADPH-oxidase and its associated whole-cell H+ current in human neutrophils by recombinant human tumor necrosis factor α and formyl-methionylleucyl-phenylalanine. J Biol Chem 1995;270:13124-32.
51. Ellis JA, Mayer SJ, Jones OT. The effect of the NADPH oxidase inhibitor diphenyleneiodonium on aerobic and anaerobic microbicidal activities of human neutrophils. Biochem J 1988;251:887-91.
52. Isaev NK, Stelmashook EV, Ruscher K, Andreeva NA, Zorov DB. Menadione reduces rotenone-induced cell death in cerebellar granule neurons. Neuroreport 2004;15:2227-31.
53. Andersen LD, Remington P, Trentham-Dietz A, Reeves M. Assessing a decade of progress in cancer control. Oncologist 2002;7:200-4.
54. Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, Wingo PA, Howe HL, Anderson RN, Edwards BK. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004;101:3-27.
55. Zhu K, Gerbino E, Beaupre DM, Mackley PA, Muro-Cacho C, Beam C, Hamilton AD, Lichtenheld MG, Kerr WG, Dalton W, Alsina M, Sebti SM. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood 2005;105:4759-66.
56. Dempke WC. Farnesyltransferase inhibitors - a novel approach in the treatment of advanced pancreatic carcinomas. Anticancer Res 2003;23:813-18.